应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
KALV Kalvista Pharmaceuticals Inc
盘后交易 01-09 18:37:51 EST
16.80
+0.98
+6.19%
盘后
16.58
-0.22
-1.34%
18:06 EST
最高
19.00
最低
16.01
成交量
501.62万
今开
18.60
昨收
15.82
日振幅
18.90%
总市值
8.49亿
流通市值
4.67亿
总股本
5,055万
成交额
8,892万
换手率
18.04%
流通股本
2,781万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Kalvista制药公布Ekterly®强劲上市进展及2025年第四季度与全年初步营收业绩
美股速递 · 01-09 05:06
Kalvista制药公布Ekterly®强劲上市进展及2025年第四季度与全年初步营收业绩
Kalvista Pharmaceuticals在日本获得Ekterly® (Sebetralstat)的批准,成为首个也是唯一的口服按需治疗遗传性水肿的药物
美股速递 · 2025-12-22
Kalvista Pharmaceuticals在日本获得Ekterly® (Sebetralstat)的批准,成为首个也是唯一的口服按需治疗遗传性水肿的药物
Kalvista Pharmaceuticals将于2025年11月11日召开第三季度财务业绩电话会议和网络广播
美股速递 · 2025-11-03
Kalvista Pharmaceuticals将于2025年11月11日召开第三季度财务业绩电话会议和网络广播
Kalvista Pharmaceuticals任命Bilal Arif为首席运营官,Linea Aspesi为首席人事官
美股速递 · 2025-10-06
Kalvista Pharmaceuticals任命Bilal Arif为首席运营官,Linea Aspesi为首席人事官
生物科技股集体重挫!报道称特朗普政府将儿童死亡甩锅新冠疫苗接种
华尔街见闻 · 2025-09-13
生物科技股集体重挫!报道称特朗普政府将儿童死亡甩锅新冠疫苗接种
Kalvista Pharmaceuticals Inc将于2025年9月11日发布运营更新及财季业绩报告
美股速递 · 2025-09-04
Kalvista Pharmaceuticals Inc将于2025年9月11日发布运营更新及财季业绩报告
Kalvista Pharmaceuticals, Inc.盘中异动 下午盘急速下挫5.14%报13.83美元
市场透视 · 2025-07-29
Kalvista Pharmaceuticals, Inc.盘中异动 下午盘急速下挫5.14%报13.83美元
Kalvista Pharmaceuticals, Inc.盘中异动 大幅拉升5.11%报11.43美元
市场透视 · 2025-03-05
Kalvista Pharmaceuticals, Inc.盘中异动 大幅拉升5.11%报11.43美元
Citizens Capital Markets:重申KalVista Pharma(KALV.US)评级,由优于大市调整至优于大市评级, 目标价由19.00美元调整至19.00美元。
金融界 · 2025-03-03
Citizens Capital Markets:重申KalVista Pharma(KALV.US)评级,由优于大市调整至优于大市评级, 目标价由19.00美元调整至19.00美元。
Kalvista Pharmaceuticals, Inc.盘中异动 急速拉升5.08%
市场透视 · 2025-03-01
Kalvista Pharmaceuticals, Inc.盘中异动 急速拉升5.08%
Kalvista Pharmaceuticals, Inc.盘中异动 大幅上涨5.06%报11.32美元
市场透视 · 2025-02-26
Kalvista Pharmaceuticals, Inc.盘中异动 大幅上涨5.06%报11.32美元
Kalvista Pharmaceuticals, Inc.盘中异动 快速下跌5.45%报10.06美元
市场透视 · 2025-02-22
Kalvista Pharmaceuticals, Inc.盘中异动 快速下跌5.45%报10.06美元
Kalvista Pharmaceuticals, Inc.盘中异动 早盘股价大涨5.83%报10.35美元
市场透视 · 2025-02-19
Kalvista Pharmaceuticals, Inc.盘中异动 早盘股价大涨5.83%报10.35美元
Kalvista Pharmaceuticals, Inc.盘中异动 大幅拉升5.16%报9.37美元
市场透视 · 2025-02-04
Kalvista Pharmaceuticals, Inc.盘中异动 大幅拉升5.16%报9.37美元
KalVista Pharma(KALV.US)获摩根大通证券公司首次覆盖,给予优于大市评级, 目标价19.00美元。
金融界 · 2025-02-01
KalVista Pharma(KALV.US)获摩根大通证券公司首次覆盖,给予优于大市评级, 目标价19.00美元。
Kalvista Pharmaceuticals, Inc.盘中异动 早盘快速拉升5.46%报9.08美元
市场透视 · 2025-01-27
Kalvista Pharmaceuticals, Inc.盘中异动 早盘快速拉升5.46%报9.08美元
Kalvista Pharmaceuticals, Inc.盘中异动 早盘急速上涨5.18%
市场透视 · 2025-01-22
Kalvista Pharmaceuticals, Inc.盘中异动 早盘急速上涨5.18%
Kalvista Pharmaceuticals, Inc.盘中异动 股价大涨5.03%
市场透视 · 2025-01-16
Kalvista Pharmaceuticals, Inc.盘中异动 股价大涨5.03%
Kalvista Pharmaceuticals, Inc.盘中异动 早盘快速拉升5.95%报7.84美元
市场透视 · 2025-01-15
Kalvista Pharmaceuticals, Inc.盘中异动 早盘快速拉升5.95%报7.84美元
Kalvista Pharmaceuticals, Inc.盘中异动 早盘大幅跳水5.08%报7.45美元
市场透视 · 2025-01-13
Kalvista Pharmaceuticals, Inc.盘中异动 早盘大幅跳水5.08%报7.45美元
加载更多
公司概况
公司名称:
Kalvista Pharmaceuticals Inc
所属市场:
NASDAQ
上市日期:
--
主营业务:
KalVista Pharmaceuticals, Inc.于2004年3月26日在特拉华州注册成立。该公司是一家临床阶段制药公司,专注于发现、开发和商业化小分子蛋白酶抑制剂,用于有重大未满足需求的疾病。该公司运用他们对蛋白酶的化学和生物学的洞见,开发出具有高选择性、效力和生物利用度的口服疗法,该公司相信这将使它们成为治疗疾病的成功药物。该公司利用这些能力开发了针对遗传性血管性水肿(HAE)的新型小分子血浆激肽释放酶抑制剂。该公司还在进行一项新的口服XIIa因子(“XIIa因子”)抑制剂项目的临床前开发。该公司正在初步推进这一项目,以提供下一代HAE疗法,这也为将来扩展到其他未满足的高需求适应症提供了机会。
发行价格:
--
{"stockData":{"symbol":"KALV","market":"US","secType":"STK","nameCN":"Kalvista Pharmaceuticals Inc","latestPrice":16.8,"timestamp":1767992400000,"preClose":15.82,"halted":0,"volume":5016197,"hourTrading":{"tag":"盘后","latestPrice":16.5752,"preClose":16.8,"latestTime":"18:06 EST","volume":13384,"amount":224901.63091200002,"timestamp":1768000015232},"delay":0,"floatShares":27812263,"shares":50546293,"eps":-3.946012,"marketStatus":"盘后交易","change":0.98,"latestTime":"01-09 18:37:51 EST","open":18.6,"high":19,"low":16.01,"amount":88921557.388739,"amplitude":0.189001,"askPrice":18.29,"askSize":550,"bidPrice":16.27,"bidSize":150,"shortable":3,"etf":0,"ttmEps":-3.946012,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1768006800000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1479790800000,"exchange":"NASDAQ","adjPreClose":15.82,"preHourTrading":{"tag":"盘前","latestPrice":18.6,"preClose":15.82,"latestTime":"09:29 EST","volume":40611,"amount":748943.7978449999,"timestamp":1767968999928},"postHourTrading":{"tag":"盘后","latestPrice":16.5752,"preClose":16.8,"latestTime":"18:06 EST","volume":13384,"amount":224901.63091200002,"timestamp":1768000015232},"volumeRatio":4.071444,"impliedVol":0.7137,"impliedVolPercentile":0.3227},"requestUrl":"/m/hq/s/KALV","defaultTab":"news","newsList":[{"id":"1178822520","title":"Kalvista制药公布Ekterly®强劲上市进展及2025年第四季度与全年初步营收业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1178822520","media":"美股速递","labels":["productRelease","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178822520?lang=zh_cn&edition=full","pubTime":"2026-01-09 05:06","pubTimestamp":1767906375,"startTime":"0","endTime":"0","summary":"Kalvista制药公司近日发布了其创新药物Ekterly®上市后的积极动态,同时披露了2025财年第四季度及全年的初步营收数据。初步结果显示,Ekterly®的市场推广势头强劲,为公司全年营收做出了显著贡献。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KALV","BK4139"],"gpt_icon":0},{"id":"1149381360","title":"Kalvista Pharmaceuticals在日本获得Ekterly® (Sebetralstat)的批准,成为首个也是唯一的口服按需治疗遗传性水肿的药物","url":"https://stock-news.laohu8.com/highlight/detail?id=1149381360","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149381360?lang=zh_cn&edition=full","pubTime":"2025-12-22 19:01","pubTimestamp":1766401271,"startTime":"0","endTime":"0","summary":"Kalvista Pharmaceuticals在日本获得Ekterly® (Sebetralstat)的批准,成为首个也是唯一的口服按需治疗遗传性水肿的药物。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KALV","BK4139"],"gpt_icon":0},{"id":"1148702813","title":"Kalvista Pharmaceuticals将于2025年11月11日召开第三季度财务业绩电话会议和网络广播","url":"https://stock-news.laohu8.com/highlight/detail?id=1148702813","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148702813?lang=zh_cn&edition=full","pubTime":"2025-11-03 20:01","pubTimestamp":1762171276,"startTime":"0","endTime":"0","summary":"Kalvista Pharmaceuticals将于2025年11月11日召开第三季度财务业绩电话会议和网络广播","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KALV"],"gpt_icon":0},{"id":"1104662770","title":"Kalvista Pharmaceuticals任命Bilal Arif为首席运营官,Linea Aspesi为首席人事官","url":"https://stock-news.laohu8.com/highlight/detail?id=1104662770","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104662770?lang=zh_cn&edition=full","pubTime":"2025-10-06 19:02","pubTimestamp":1759748576,"startTime":"0","endTime":"0","summary":"Kalvista Pharmaceuticals宣布任命Bilal Arif担任公司首席运营官,同时任命Linea Aspesi为首席人事官。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KALV"],"gpt_icon":0},{"id":"2567190639","title":"生物科技股集体重挫!报道称特朗普政府将儿童死亡甩锅新冠疫苗接种","url":"https://stock-news.laohu8.com/highlight/detail?id=2567190639","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567190639?lang=zh_cn&edition=full","pubTime":"2025-09-13 06:38","pubTimestamp":1757716705,"startTime":"0","endTime":"0","summary":"研发新冠疫苗的BioNTech盘中跌超10%、莫德纳跌超7%、Novavax跌超4%。投资者担心,如果特朗普政府进一步收紧疫苗接种政策,可能对疫苗制造商的业务造成重大冲击,特别是对莫德纳这类高度依赖新冠疫苗收入的公司。更新中","market":"us","thumbnail":"https://static.tigerbbs.com/632b4e916ff966270173f4303843021f","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/632b4e916ff966270173f4303843021f"],"rights":{"source":"wallstreetcn_hot_news","url":"https://wallstreetcn.com/articles/3755508","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"ae8bc75ba4d1918dcafc0476d86c6d53","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3755508","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"生物科技股集体重挫!报道称特朗普政府将儿童死亡甩锅新冠疫苗接种","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"wallstreetcn_hot_news","symbols":["PGEN","MRNA","PFE","KALV","PSNL","MRK","BK4009","STRO","SRPT","AZN","NVS","TRVI","BNTX","TARS","TVTX","BMY","ARCT","ABUS","NVAX"],"gpt_icon":1},{"id":"1157351096","title":"Kalvista Pharmaceuticals Inc将于2025年9月11日发布运营更新及财季业绩报告","url":"https://stock-news.laohu8.com/highlight/detail?id=1157351096","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157351096?lang=zh_cn&edition=full","pubTime":"2025-09-04 19:07","pubTimestamp":1756984059,"startTime":"0","endTime":"0","summary":"Kalvista Pharmaceuticals Inc将于2025年9月11日发布运营更新及财季财务业绩报告。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KALV","BK4139"],"gpt_icon":0},{"id":"2555706795","title":"Kalvista Pharmaceuticals, Inc.盘中异动 下午盘急速下挫5.14%报13.83美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2555706795","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555706795?lang=zh_cn&edition=full","pubTime":"2025-07-29 02:53","pubTimestamp":1753728805,"startTime":"0","endTime":"0","summary":"北京时间2025年07月29日02时53分,Kalvista Pharmaceuticals, Inc.股票出现波动,股价快速下挫5.14%。Kalvista Pharmaceuticals, Inc.股票所在的生物技术行业中,整体跌幅为0.21%。其相关个股中,Celcuity Inc.、Protagenic Therapeutics Inc C/Wts 26/04/2026 、Lixte Biotechnology Holdings Inc C/Wts 30/11/2025 涨幅较大,Aim Immunotech Inc.、Tnf Pharmaceuticals, Inc.、Cervomed Inc.较为活跃,换手率分别为559.15%、322.30%、134.98%,振幅较大的相关个股有Aim Immunotech Inc.、Celcuity Inc.、Rocket Pharmaceuticals Inc C/Wts 02/09/2026 ,振幅分别为158.93%、82.93%、75.48%。Kalvista Pharmaceuticals, Inc.公司简介:KalVista Pharmaceuticals Inc 是一家制药公司,为未满足需求的患有罕见疾病的患者开发并提供口服疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729025326a4682979&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729025326a4682979&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0012050646.USD","IE00BLDYK493.USD","LU1169590202.USD","LU1169589451.USD","BK4198","HAE","IE00B64QTZ34.USD","KALV","LU0106261612.USD","LU0205193047.USD","LU0205194284.USD","BK4139"],"gpt_icon":0},{"id":"2517985069","title":"Kalvista Pharmaceuticals, Inc.盘中异动 大幅拉升5.11%报11.43美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517985069","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517985069?lang=zh_cn&edition=full","pubTime":"2025-03-05 04:27","pubTimestamp":1741120066,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日04时27分,Kalvista Pharmaceuticals, Inc.股票出现波动,股价急速拉升5.11%。Kalvista Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为0.21%。其相关个股中,Rapport Therapeutics, Inc.、Lakeshore Biopharma Co Ltd C/Wts 15/03/2028 、Estrella Immunopharma Inc C/Wts 29/09/2028涨幅较大,Aeon Biopharma, Inc.、Protagenic Therapeutics, Inc.、Windtree Therapeutics, Inc.较为活跃,换手率分别为1330.19%、1258.60%、1224.41%,振幅较大的相关个股有Cyclacel Pharmaceuticals Inc 6% Cnv Pfd Usd、Protagenic Therapeutics Inc C/Wts 29/04/2026 、Plus Therapeutics, Inc.,振幅分别为122.48%、68.89%、68.09%。Kalvista Pharmaceuticals, Inc.公司简介:KalVista Pharmaceuticals Inc 是一家专注于发现、开发和商业化用于一系列疾病的小分子蛋白酶抑制剂的制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025030504274696399744&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025030504274696399744&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KALV","BK4139"],"gpt_icon":0},{"id":"2516637427","title":"Citizens Capital Markets:重申KalVista Pharma(KALV.US)评级,由优于大市调整至优于大市评级, 目标价由19.00美元调整至19.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516637427","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516637427?lang=zh_cn&edition=full","pubTime":"2025-03-03 23:11","pubTimestamp":1741014689,"startTime":"0","endTime":"0","summary":"Citizens Capital Markets:重申KalVista Pharma(KALV.US)评级,由优于大市调整至优于大市评级, 目标价由19.00美元调整至19.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/03231148494584.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["KALV"],"gpt_icon":0},{"id":"2516148371","title":"Kalvista Pharmaceuticals, Inc.盘中异动 急速拉升5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516148371","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516148371?lang=zh_cn&edition=full","pubTime":"2025-03-01 00:36","pubTimestamp":1740760606,"startTime":"0","endTime":"0","summary":"北京时间2025年03月01日00时36分,Kalvista Pharmaceuticals, Inc.股票出现异动,股价快速拉升5.08%。Kalvista Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为0.25%。其相关个股中,Bioxcel Therapeutics, Inc.、Camp4 Therapeutics Corporation、Revolution Medicines Inc C/Wts 17/12/2026 涨幅较大,Bioxcel Therapeutics, Inc.、Enveric Biosciences, Inc.、Virpax Pharmaceuticals, Inc.较为活跃,换手率分别为2922.48%、491.11%、364.17%,振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Lakeshore Biopharma Co Ltd C/Wts 15/03/2028 、Nrx Pharmaceuticals Inc C/Wts 24/05/2026 ,振幅分别为57.80%、46.60%、43.95%。Kalvista Pharmaceuticals, Inc.公司简介:KalVista Pharmaceuticals Inc 是一家专注于发现、开发和商业化用于一系列疾病的小分子蛋白酶抑制剂的制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503010036479634359a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503010036479634359a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","KALV"],"gpt_icon":0},{"id":"2514542788","title":"Kalvista Pharmaceuticals, Inc.盘中异动 大幅上涨5.06%报11.32美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514542788","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514542788?lang=zh_cn&edition=full","pubTime":"2025-02-26 23:38","pubTimestamp":1740584333,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日23时38分,Kalvista Pharmaceuticals, Inc.股票出现波动,股价大幅上涨5.06%。Kalvista Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为0.04%。其相关个股中,Enveric Biosciences, Inc.、Pds Biotechnology Corporation、Humacyte Inc C/Wts 27/08/2026 涨幅较大,Enveric Biosciences, Inc.、Organovo Holdings, Inc.、Aeon Biopharma, Inc.较为活跃,换手率分别为5229.01%、197.73%、185.00%,振幅较大的相关个股有Enveric Biosciences, Inc.、Organovo Holdings, Inc.、Humacyte Inc C/Wts 27/08/2026 ,振幅分别为161.02%、43.31%、39.47%。Kalvista Pharmaceuticals, Inc.公司简介:KalVista Pharmaceuticals Inc 是一家专注于发现、开发和商业化用于一系列疾病的小分子蛋白酶抑制剂的制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502262338539893b7af&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502262338539893b7af&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","KALV"],"gpt_icon":0},{"id":"2513921966","title":"Kalvista Pharmaceuticals, Inc.盘中异动 快速下跌5.45%报10.06美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513921966","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513921966?lang=zh_cn&edition=full","pubTime":"2025-02-22 02:54","pubTimestamp":1740164096,"startTime":"0","endTime":"0","summary":"北京时间2025年02月22日02时54分,Kalvista Pharmaceuticals, Inc.股票出现异动,股价大幅下跌5.45%。Kalvista Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为0.33%。其相关个股中,Conduit Pharmaceuticals Inc C/Wts 22/09/2028、Revolution Medicines Inc C/Wts 17/12/2026 、Invivyd, Inc.涨幅较大,Aditxt, Inc.、Nkgen Biotech, Inc.、Osr Holdings, Inc.较为活跃,换手率分别为293.98%、247.56%、136.47%,振幅较大的相关个股有Osr Holdings, Inc.、Invivyd, Inc.、Conduit Pharmaceuticals Inc C/Wts 22/09/2028,振幅分别为76.52%、70.25%、61.26%。Kalvista Pharmaceuticals, Inc.公司简介:KalVista Pharmaceuticals Inc 是一家专注于发现、开发和商业化用于一系列疾病的小分子蛋白酶抑制剂的制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222025456962bb494&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222025456962bb494&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","KALV"],"gpt_icon":0},{"id":"2512485671","title":"Kalvista Pharmaceuticals, Inc.盘中异动 早盘股价大涨5.83%报10.35美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512485671","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512485671?lang=zh_cn&edition=full","pubTime":"2025-02-19 23:00","pubTimestamp":1739977248,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日23时00分,Kalvista Pharmaceuticals, Inc.股票出现异动,股价大幅上涨5.83%。截至发稿,该股报10.35美元/股,成交量5.089万股,换手率0.10%,振幅5.93%。Kalvista Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为0.49%。Kalvista Pharmaceuticals, Inc.公司简介:KalVista Pharmaceuticals Inc 是一家专注于发现、开发和商业化用于一系列疾病的小分子蛋白酶抑制剂的制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219230048a24c01df&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219230048a24c01df&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KALV","BK4139"],"gpt_icon":0},{"id":"2508124256","title":"Kalvista Pharmaceuticals, Inc.盘中异动 大幅拉升5.16%报9.37美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2508124256","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2508124256?lang=zh_cn&edition=full","pubTime":"2025-02-04 03:11","pubTimestamp":1738609878,"startTime":"0","endTime":"0","summary":"北京时间2025年02月04日03时11分,Kalvista Pharmaceuticals, Inc.股票出现异动,股价急速拉升5.16%。Kalvista Pharmaceuticals, Inc.股票所在的生物技术行业中,整体跌幅为0.28%。其相关个股中,Invivyd, Inc.、Hcw Biologics Inc.、Gh Research Plc涨幅较大,Cyclerion Therapeutics, Inc.、Hcw Biologics Inc.、Briacell Therapeutics Corp.较为活跃,换手率分别为744.10%、723.79%、469.51%,振幅较大的相关个股有Hcw Biologics Inc.、Invivyd, Inc.、Briacell Therapeutics Corp.,振幅分别为170.13%、151.80%、63.94%。Kalvista Pharmaceuticals, Inc.公司简介:KalVista Pharmaceuticals Inc 是一家专注于发现、开发和商业化用于一系列疾病的小分子蛋白酶抑制剂的制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250204031118987994e5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250204031118987994e5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","KALV"],"gpt_icon":0},{"id":"2508998384","title":"KalVista Pharma(KALV.US)获摩根大通证券公司首次覆盖,给予优于大市评级, 目标价19.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2508998384","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2508998384?lang=zh_cn&edition=full","pubTime":"2025-02-01 01:13","pubTimestamp":1738343582,"startTime":"0","endTime":"0","summary":"KalVista Pharma(KALV.US)获摩根大通证券公司首次覆盖,给予优于大市评级, 目标价19.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/01011347922529.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["159848","399975","KALV"],"gpt_icon":0},{"id":"2506092873","title":"Kalvista Pharmaceuticals, Inc.盘中异动 早盘快速拉升5.46%报9.08美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2506092873","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2506092873?lang=zh_cn&edition=full","pubTime":"2025-01-27 23:18","pubTimestamp":1737991132,"startTime":"0","endTime":"0","summary":"北京时间2025年01月27日23时18分,Kalvista Pharmaceuticals, Inc.股票出现异动,股价大幅拉升5.46%。Kalvista Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为0.99%。其相关个股中,Akero Therapeutics, Inc.、Onconetix, Inc.、89Bio, Inc.涨幅较大,Onconetix, Inc.、Evaxion Biotech As、Dogwood Therapeutics, Inc.较为活跃,换手率分别为1741.10%、191.47%、171.32%,振幅较大的相关个股有Onconetix, Inc.、Conduit Pharmaceuticals Inc C/Wts 22/09/2028、Immatics N V C/Wts 01/07/2025 ,振幅分别为85.35%、65.16%、61.25%。Kalvista Pharmaceuticals, Inc.公司简介:KalVista Pharmaceuticals Inc 是一家专注于发现、开发和商业化用于一系列疾病的小分子蛋白酶抑制剂的制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250127231852a23174ac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250127231852a23174ac&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","KALV"],"gpt_icon":0},{"id":"2505205827","title":"Kalvista Pharmaceuticals, Inc.盘中异动 早盘急速上涨5.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2505205827","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2505205827?lang=zh_cn&edition=full","pubTime":"2025-01-22 00:15","pubTimestamp":1737476120,"startTime":"0","endTime":"0","summary":"北京时间2025年01月22日00时15分,Kalvista Pharmaceuticals, Inc.股票出现异动,股价大幅上涨5.18%。Kalvista Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为1.63%。其相关个股中,Channel Therapeutics Corporation、Cardio Diagnostics Holdings Inc C/Wts To Pur Com、Dogwood Therapeutics, Inc.涨幅较大,Dogwood Therapeutics, Inc.、Channel Therapeutics Corporation、Dermata Therapeutics, Inc.较为活跃,换手率分别为755.07%、470.06%、182.16%,振幅较大的相关个股有Channel Therapeutics Corporation、Klotho Neurosciences Inc C/Wts 21/06/2029 、Dogwood Therapeutics, Inc.,振幅分别为96.32%、41.33%、38.48%。Kalvista Pharmaceuticals, Inc.公司简介:KalVista Pharmaceuticals Inc 是一家专注于发现、开发和商业化用于一系列疾病的小分子蛋白酶抑制剂的制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250122001520986e465c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250122001520986e465c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","KALV"],"gpt_icon":0},{"id":"2504308914","title":"Kalvista Pharmaceuticals, Inc.盘中异动 股价大涨5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2504308914","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2504308914?lang=zh_cn&edition=full","pubTime":"2025-01-16 23:54","pubTimestamp":1737042876,"startTime":"0","endTime":"0","summary":"北京时间2025年01月16日23时54分,Kalvista Pharmaceuticals, Inc.股票出现波动,股价急速上涨5.03%。Kalvista Pharmaceuticals, Inc.股票所在的生物技术行业中,整体跌幅为0.61%。其相关个股中,Aeon Biopharma, Inc.、Silexion Therapeutics Corp C/Wts Exp 15/08/2029 、Rocket Pharmaceuticals Inc C/Wts 02/09/2026 涨幅较大,Aditxt, Inc.、Palisade Bio, Inc.、Silexion Therapeutics Corp较为活跃,换手率分别为1777.03%、369.61%、247.72%,振幅较大的相关个股有Silexion Therapeutics Corp C/Wts Exp 15/08/2029 、Aeon Biopharma, Inc.、Lakeshore Biopharma Co Ltd C/Wts 15/03/2028 ,振幅分别为131.33%、104.84%、76.46%。Kalvista Pharmaceuticals, Inc.公司简介:KalVista Pharmaceuticals Inc 是一家专注于发现、开发和商业化用于一系列疾病的小分子蛋白酶抑制剂的制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250116235436a2247320&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250116235436a2247320&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","KALV"],"gpt_icon":0},{"id":"2503571642","title":"Kalvista Pharmaceuticals, Inc.盘中异动 早盘快速拉升5.95%报7.84美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2503571642","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503571642?lang=zh_cn&edition=full","pubTime":"2025-01-15 22:31","pubTimestamp":1736951466,"startTime":"0","endTime":"0","summary":"北京时间2025年01月15日22时31分,Kalvista Pharmaceuticals, Inc.股票出现异动,股价快速拉升5.95%。Kalvista Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为0.68%。其相关个股中,Os Therapies Incorporated、Exicure, Inc.、Eterna Therapeutics Inc.涨幅较大,Windtree Therapeutics, Inc.、Os Therapies Incorporated、Phio Pharmaceuticals Corp.较为活跃,换手率分别为183.55%、55.23%、50.88%,振幅较大的相关个股有Vincerx Pharma, Inc.、Onconetix, Inc.、Viracta Therapeutics, Inc.,振幅分别为10.72%、9.31%、9.18%。Kalvista Pharmaceuticals, Inc.公司简介:KalVista Pharmaceuticals Inc 是一家专注于发现、开发和商业化用于一系列疾病的小分子蛋白酶抑制剂的制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250115223106a222fd78&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250115223106a222fd78&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KALV","BK4139"],"gpt_icon":0},{"id":"2503116589","title":"Kalvista Pharmaceuticals, Inc.盘中异动 早盘大幅跳水5.08%报7.45美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2503116589","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503116589?lang=zh_cn&edition=full","pubTime":"2025-01-13 22:52","pubTimestamp":1736779956,"startTime":"0","endTime":"0","summary":"北京时间2025年01月13日22时52分,Kalvista Pharmaceuticals, Inc.股票出现波动,股价急速下挫5.08%。Kalvista Pharmaceuticals, Inc.股票所在的生物技术行业中,整体跌幅为1.42%。其相关个股中,Phio Pharmaceuticals Corp.、Salarius Pharmaceuticals, Inc.、Kairos Pharma, Ltd.涨幅较大,Phio Pharmaceuticals Corp.、Salarius Pharmaceuticals, Inc.、Silexion Therapeutics Corp较为活跃,换手率分别为4957.92%、3054.99%、406.27%,振幅较大的相关个股有Kairos Pharma, Ltd.、Salarius Pharmaceuticals, Inc.、Phio Pharmaceuticals Corp.,振幅分别为118.35%、104.79%、92.90%。Kalvista Pharmaceuticals, Inc.公司简介:KalVista Pharmaceuticals Inc 是一家专注于发现、开发和商业化用于一系列疾病的小分子蛋白酶抑制剂的制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501132252379602575b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501132252379602575b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","KALV"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kalvista.com","stockEarnings":[{"period":"1week","weight":-0.0204},{"period":"1month","weight":-0.021},{"period":"3month","weight":0.3757},{"period":"6month","weight":0.0895},{"period":"1year","weight":0.9199},{"period":"ytd","weight":-0.0204}],"compareEarnings":[{"period":"1week","weight":0.0111},{"period":"1month","weight":0.0095},{"period":"3month","weight":0.0559},{"period":"6month","weight":0.1057},{"period":"1year","weight":0.1697},{"period":"ytd","weight":0.0111}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"KalVista Pharmaceuticals, Inc.于2004年3月26日在特拉华州注册成立。该公司是一家临床阶段制药公司,专注于发现、开发和商业化小分子蛋白酶抑制剂,用于有重大未满足需求的疾病。该公司运用他们对蛋白酶的化学和生物学的洞见,开发出具有高选择性、效力和生物利用度的口服疗法,该公司相信这将使它们成为治疗疾病的成功药物。该公司利用这些能力开发了针对遗传性血管性水肿(HAE)的新型小分子血浆激肽释放酶抑制剂。该公司还在进行一项新的口服XIIa因子(“XIIa因子”)抑制剂项目的临床前开发。该公司正在初步推进这一项目,以提供下一代HAE疗法,这也为将来扩展到其他未满足的高需求适应症提供了机会。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.01212},{"month":2,"riseRate":0.555556,"avgChangeRate":0.181118},{"month":3,"riseRate":0.444444,"avgChangeRate":-0.059731},{"month":4,"riseRate":0.444444,"avgChangeRate":0.0305},{"month":5,"riseRate":0.444444,"avgChangeRate":-0.040416},{"month":6,"riseRate":0.555556,"avgChangeRate":-0.005524},{"month":7,"riseRate":0.555556,"avgChangeRate":0.039581},{"month":8,"riseRate":0.555556,"avgChangeRate":0.149368},{"month":9,"riseRate":0.222222,"avgChangeRate":-0.065906},{"month":10,"riseRate":0.333333,"avgChangeRate":0.007901},{"month":11,"riseRate":0.555556,"avgChangeRate":0.074914},{"month":12,"riseRate":0.5,"avgChangeRate":0.048897}],"exchange":"NASDAQ","name":"Kalvista Pharmaceuticals Inc","nameEN":"Kalvista Pharmaceuticals Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Kalvista Pharmaceuticals Inc(KALV)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Kalvista Pharmaceuticals Inc(KALV)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Kalvista Pharmaceuticals Inc,KALV,Kalvista Pharmaceuticals Inc股票,Kalvista Pharmaceuticals Inc股票老虎,Kalvista Pharmaceuticals Inc股票老虎国际,Kalvista Pharmaceuticals Inc行情,Kalvista Pharmaceuticals Inc股票行情,Kalvista Pharmaceuticals Inc股价,Kalvista Pharmaceuticals Inc股市,Kalvista Pharmaceuticals Inc股票价格,Kalvista Pharmaceuticals Inc股票交易,Kalvista Pharmaceuticals Inc股票购买,Kalvista Pharmaceuticals Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Kalvista Pharmaceuticals Inc(KALV)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Kalvista Pharmaceuticals Inc(KALV)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}